The Supreme Court revoked claims 1 to 4, and found claim 5 to be novel and inventive but not infringed, because the result of defendant’s machine was not obtained by the claimed means. The court sanctioned the appeal court’s decision that the doctrine of equivalence could not be applied. Click here  for the full text of…

In a 2-1 decision issued August 3, 2012 in Momenta Pharmaceuticals, Inc. v. Amphastar Pharmaceuticals, Inc., the U.S. Court of Appeals for the Federal Circuit held that the safe harbor provisions of 35 USC § 271(e)(1) can shield the defendants from liability for patent infringement arising out of their use of patented methods to satisfy…

The interesting six-jurisdiction patent case between two of the world’s leading enzyme manufacturers, the Danish companies Danisco A/S (now part of DuPont) and Novozymes A/S has already been subject to earlier blogs both here and several times on EPLAW and PatLit. To recap the story briefly, Novozymes started the proceedings by applying for a preliminary…

The High Court considered the extent to which a claim for damages in a patent infringement case could be extended at the damages inquiry stage. It found that whilst it is just and convenient to extend the inquiry to infringing acts of the same type as that on which the Court in the main action…

Regarding the interpretation of “offering for the purpose” (of making, using etc.) in the sense of Article 53(1)(b) Dutch Patent Act, the Supreme Court held that offering has to be construed broadly and is not restricted to offering for sale. The defendant submitted its generic product for listing in G-Standaard, the database for medicinal products…

The objection raised by the opponent that the protected subject matter of a divisional application extends beyond the content of the parent application does not represent a “fresh ground for opposition”,. This bbecause in the present case i.c. the opposition division hadhas earlier raised an unrelated objection earlier, holdinstating that the patent based on the…